- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Patent holdings for IPC class C07D 261/20
Total number of patents in this class: 375
10-year publication summary
|
35
|
26
|
26
|
21
|
25
|
22
|
24
|
16
|
26
|
8
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4789 |
16 |
| President and Fellows of Harvard College | 6060 |
11 |
| Purdue Pharma L.P. | 492 |
11 |
| BioCryst Pharmaceuticals, Inc. | 180 |
10 |
| Theravance Biopharma R&D IP, LLC | 416 |
9 |
| Abbvie Inc. | 1837 |
7 |
| University of Georgia Research Foundation, Inc. | 1067 |
7 |
| Enanta Pharmaceuticals, Inc. | 433 |
6 |
| Calico Life Sciences LLC | 106 |
6 |
| Abiogen Pharma S.p.A. | 154 |
5 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 861 |
5 |
| SynAffix B.V. | 119 |
5 |
| Ctxt Pty Ltd | 59 |
5 |
| Sumitomo Pharma Co., Ltd. | 550 |
5 |
| Merck Sharp & Dohme LLC | 3737 |
5 |
| F. Hoffmann-La Roche AG | 7847 |
4 |
| CHDI Foundation, Inc. | 106 |
4 |
| Sunshine Lake Pharma Co., Ltd. | 619 |
4 |
| Tetraphase Pharmaceuticals, Inc. | 52 |
4 |
| Yale University | 2499 |
4 |
| Other owners | 242 |